Borregaard ASA (0QB7)
London Exchange · UK · prices in NOK · close of 23 Oct 2026
Key indicators
| Last close | NOK 141.70 |
|---|---|
| 52-week range | 137.80 – 200.50 |
| Return, 1 month / 3 months | −5.6% / −11.4% |
| Return, 1 year / 3 years | −22.4% / +2.0% |
| Trend | Below its 200-day average |
| RSI (14) | 34 |
| Volatility (1 year) | 23.5% |
| Worst drawdown (1 year) | -29.2% |
| Average daily value traded | 1.13M NOK |
| Dividend yield | 3.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Borregaard ASA is a Norwegian biorefinery company that turns timber and plant biomass into specialty chemicals and biomaterials. Its products include lignin-based binders and dispersants, cellulose derivatives, vanillin and bioethanol, which are supplied to customers in construction, agriculture, food, pharmaceuticals and other industrial markets. The company is based in Sarpsborg, Norway, and serves customers in many countries around the world.
The shares are listed on the London Exchange in UK under the code 0QB7, and the price on this page is in Norwegian kroner (NOK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Borregaard ASA (0QB7) trades on the London Exchange in UK. It last closed at NOK 141.70 on 23 October 2026.
Its price-based Market X-Ray is 42 out of 100 (a weak price profile), ranking 2,502 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 22.4% and over the last three months it fell 11.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 29 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -11.0% | ||
| From 52-week high | -29.2% | ||
| Momentum | 23 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -11.4% | ||
| 6-month return | -15.5% | ||
| 12-month return, skipping the last month | -17.8% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 23.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.2% | ||
| Liquidity | 54 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.13M NOK | ||
| Zero-volume days | 10.0% | ||
| Income | 49 · Weak | Dividend is small or irregular. | |
| Dividend yield | 3.4% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | −4.8% |
|---|---|
| 1 month | −5.6% |
| 3 months | −11.4% |
| 6 months | −15.5% |
| 1 year | −22.4% |
| 3 years | +2.0% |
| 5 years | −25.4% |
Signals
| 50-day / 200-day average | 151.71 / 159.27 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.00 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Apr 2026 | NOK 4.7500 |
| 11 Apr 2025 | NOK 4.2500 |
| 12 Apr 2024 | NOK 3.7500 |
| 19 Apr 2023 | NOK 3.2500 |
| 8 Apr 2022 | NOK 2.7500 |
| 15 Apr 2021 | NOK 2.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.